Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial [Yahoo! Finance]
Hepion Pharmaceuticals, Inc. (HEPA)
Last hepion pharmaceuticals, inc. earnings: 11/14 05:17 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multi-center, double-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized. To date, approximately 80 subjects have completed their Day 365 visits and are evaluable for both safety and efficacy. An additional 40 subjects will provide significant safety data for evaluation. These patients will be added to our existing safety database. “We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constr
Show less
Read more
Impact Snapshot
Event Time:
HEPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HEPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HEPA alerts
High impacting Hepion Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
HEPA
News
- Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialGlobeNewswire
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellGlobeNewswire
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds [Yahoo! Finance]Yahoo! Finance
HEPA
Earnings
- 11/20/23 - Miss
HEPA
Sec Filings
- 4/16/24 - Form 10-K
- 4/1/24 - Form NT
- 3/7/24 - Form 4
- HEPA's page on the SEC website